Anlon Healthcare Investor Presentation: Q2 FY27 Highlights
Anlon Healthcare presented its Q2 FY27 investor update. The company is expanding into biologics and medical devices. Consolidated revenue for Q2 FY27 reached ₹10,561.0 lakhs (up 102.3% YoY), with PAT at ₹1,717.8 lakhs (up 84.4% YoY). H1 FY27 revenue was ₹19,317.2 lakhs (up 125.9% YoY).
The presentation covers substantial financial growth and strategic diversification into high-potential areas like biologics and medical devices, which are likely to have a significant impact on the company's future performance and market position.
The announcement details significant year-on-year growth in revenue, EBITDA, and PAT, along with strategic expansion into new segments like biologics and medical devices, indicating positive company performance and future prospects.
Anlon Healthcare Limited has released its investor presentation for the second quarter of the financial year 2026-27 (Q2 FY27). The company is evolving into an integrated pharmaceutical platform, expanding its presence across industrial chemicals, intermediates, APIs, formulations, biologics, and medical devices, supported by a dedicated CDMO vertical.
The company has strategically grown through acquisitions, integrating Apiqo Organics, Bizotic Lifescience, and Anlon Medicos, and has also incorporated new subsidiaries, Anlon Biologics and Anlon Medicare, to extend its platform into peptides, biosimilars, biological compositions, and surgical implants.
Anlon Healthcare is focusing on driving growth through capacity expansion, CDMO commercialization, new formulations, and deeper vertical integration. The company is also scaling its presence in regulated export markets, aiming for a higher export mix as DMF-backed products commercialize. It continues to strengthen its R&D and product development capabilities.
Financially, for Q2 FY27, the company reported consolidated revenue of ₹10,561.0 lakhs, a significant increase of 102.3% year-on-year. EBITDA grew by 84.1% to ₹2,524.1 lakhs, and Profit After Tax (PAT) increased by 84.4% to ₹1,717.8 lakhs. For the half-year ended September 2026 (H1 FY27), revenue stood at ₹19,317.2 lakhs, up 125.9% year-on-year, with EBITDA up 104.7% and PAT up 97.9%.
What to do with a filing like this
Anlon Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anlon Healthcare Limited. Read the original for the full detail.